The role of cytokines and chemokines in the development of steatohepatitis

被引:103
作者
Lalor, Patricia F. [1 ]
Faint, Jeff [1 ]
Aarbodem, York [1 ]
Hubscher, Stefan G. [1 ]
Adams, David H. [1 ]
机构
[1] Univ Birmingham, Sch Med, Inst Biomed Sci, Liver Res Grp,MRC Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England
基金
英国医学研究理事会;
关键词
endotholium; steatohepatitis; chemokines; ethanol; inflammation; adhesion molecules;
D O I
10.1055/s-2007-979470
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) share similar morphological characteristics despite the obvious etiological differences between the two conditions. In both conditions the first manifestation of injury is the accumulation of fat within hepatocytes (steatosis), and in a proportion of patients this is followed by the development of necroinflammatory activity that leads to cirrhosis. Steatosis alone is considered to be relatively innocuous and is usually reversible, and it is the development of liver cell ballooning and inflammation (steatohepatitis) that determines whether a patient progresses to irreversible liver damage and fibrosis. This has led to the two-hit theory in which the first hit is accumulation of fat in the liver and the second hit involves all inflammatory insult or challenge to the liver, for example, through oxidative stress or ill response to pathogenic stimuli such as endotoxin. Although the nature of the hits remains poorly understood, it is clear that the critical event in progression is the development of inflammation, and the fact that it is impossible to distinguish alcoholic from nonalcoholic steatohepatitis on histological grounds suggests that common pathogenic mechanisms are involved. We focus on the role of cytokines and particularly chemokines in instigating and driving the inflammatory infiltrate in steatohepatitis. A better understanding of this process might allow therapeutic intervention to switch off the inflammatory response before irreversible damage occurs in both ALD and NAFLD.
引用
收藏
页码:173 / 193
页数:21
相关论文
共 193 条
[1]   Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis [J].
Abiru, S ;
Migita, K ;
Maeda, Y ;
Daikoku, M ;
Ito, M ;
Ohata, K ;
Nagaoka, S ;
Matsumoto, T ;
Takil, Y ;
Kusumoto, K ;
Nakamura, M ;
Komori, A ;
Yano, K ;
Yatsuhashi, H ;
Eguchi, K ;
Ishibashi, H .
LIVER INTERNATIONAL, 2006, 26 (01) :39-45
[2]  
Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI [10.1172/JCI200420515, 10.1172/JCI200420415]
[3]   ENDOTHELIAL ACTIVATION AND CIRCULATING VASCULAR ADHESION MOLECULES IN ALCOHOLIC LIVER-DISEASE [J].
ADAMS, DH ;
BURRA, P ;
HUBSCHER, SG ;
ELIAS, E ;
NEWMAN, W .
HEPATOLOGY, 1994, 19 (03) :588-594
[4]   Expression of E-selectin and E-selectin ligands in human liver inflammation [J].
Adams, DH ;
Hubscher, SG ;
Fisher, NC ;
Williams, A ;
Robinson, M .
HEPATOLOGY, 1996, 24 (03) :533-538
[5]   Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease [J].
Adams, DH ;
Eksteen, B .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (03) :244-251
[6]   Effector mechanisms of nonsuppurative destructive cholangitis in graft-versus-host disease and allograft rejection [J].
Adams, DH ;
Afford, SC .
SEMINARS IN LIVER DISEASE, 2005, 25 (03) :281-297
[7]   Recent concepts in non-alcoholic fatty liver disease [J].
Adams, LA ;
Angulo, P .
DIABETIC MEDICINE, 2005, 22 (09) :1129-1133
[8]   A pilot trial of pentoxifylline in nonalcoholic steatohepatitis [J].
Adams, LA ;
Zein, CO ;
Angulo, P ;
Lindor, KD .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (12) :2365-2368
[9]  
Afford SC, 1998, J PATHOL, V186, P82, DOI 10.1002/(SICI)1096-9896(199809)186:1<82::AID-PATH151>3.0.CO
[10]  
2-D